Sector: MedicalMarshall Edwards, Inc. (NASDAQ: MSHL)
Headlines
- PicksThatMove.Com Announces Investment Opinion: Hot Stocks on the Move
Sep 29, 2009 03:53 PM | LEE, MSHL, YRCW
- Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Sep 22, 2009 09:52 AM | MSHL
- Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Aug 05, 2009 08:05 AM | MSHL
- Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Jul 07, 2009 08:01 AM | MSHL
- Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Jun 17, 2009 08:30 AM | MSHL
- Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Apr 14, 2009 08:20 AM | MSHL
- Board Changes at Novogen Limited Announced - Mar 23 2009 12:55PM
Mar 23, 2009 12:55 PM | MSHL
- Board Changes at Novogen Limited Announced - Mar 23 2009 11:02AM
Mar 23, 2009 10:46 AM | MSHL
- Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
Mar 19, 2009 01:08 PM | MSHL
- Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
Mar 18, 2009 11:16 AM | MSHL
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
MSHL
|
Compare to S&P
|
| YTD |
2.86 %
|
-14.87 %
|
| 4 Weeks |
-9.99 %
|
-10.96 %
|
| 12 Weeks |
1.41 %
|
-4.39 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -133.33 %
|
|
EPS Growth in Last Year: -40.00 %
|
|
Sales Growth in Last Quarter: -25.93 %
|
|
Sales Growth in Last Quarter: -77.78 %
|
|
